Lead-time and overdiagnosis estimation in neuroblastoma screening

Statistics in Medicine

Volumn 22, Issue 18, 2003, Pages 2877-2892

  Spix, Claudia ^a   Michaelis, Jörg ^a   Berthold, Frank ^b   Erttmann, Rudolf ^c   Sander, Johannes ^d   Schilling, Freimut H ^e  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d Landesgesundheitsamt Niedersachsen   (Germany)

^e KLINIKUM STUTTGART   (Germany)

Author keywords

Lead time; Neuroblastoma; Overdiagnosis; Screening

Indexed keywords

AGE DISTRIBUTION; ANALYTIC METHOD; ARTICLE; CANCER INCIDENCE; CANCER SCREENING; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EMPIRICISM; FOLLOW UP; GERMANY; HUMAN; INFANT; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; NEUROBLASTOMA; POPULATION RESEARCH; PRESCHOOL CHILD; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

AGE DISTRIBUTION; COHORT STUDIES; FALSE POSITIVE REACTIONS; GERMANY; HUMANS; INCIDENCE; INFANT; MASS SCREENING; NEUROBLASTOMA; POPULATION SURVEILLANCE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0141849053     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1533     Document Type: Article

References (27)

1. Kaatsch P, Kaletsch U, Michaelis J. Jahresbericht 1994 des Deutschen Kinderkrebsregisters (Annual report 1994 from the German Childhood Cancer Registry). Mainz, 1995.
2. Berthold F, Hunneman DH, Kaser H, Harms D, Bertram U, Erttmann R, Schilling FH, Treuner J, Zieschang J. Neuroblastoma screening: arguments from retrospective analysis of three German neuroblastoma trials. American Journal of Pediatrics, Hematoloyy and Oncology 1991; 13:8-13.
3. DeBernardi B, Carli M, Casale F, Coriculo P, di Montezemolo LC, Laurentis C, Bagnulo MS, Brisigotti M, Marchese N, Garaventa A, Felici L, Curto M, Viscoli C, Tamaro P, Rogers D, Boni L, Dini G, Bruzzi P. Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Outcome related to age and stage. Italian Cooperative Group on Neuroblastoma. Cancer 1992; 70:1625-1633.
4. DeBernardi B, Conte M, Mancini A, Donfrancesco A, Alvisi P, Tomà P, Cascale F, di Montezemolo LC, Cornelli PE, Carli M, Tonini GP, Pession A, Giaretti W, Garaventa A, Marchese N, Magillo P, Nigro M, Kotitsa Z, Tamaro P, Tamburrini A, Rogers D, Bruzzi P. Localized resectable neuroblastoma: results of the second study of the Italian Cooperative Group for Neuroblastoma. Journal of Clinical Oncology 1995; 13: 884-893.
5. Spix C, Aareleid T, Stiller C, Magnani C, Kaatsch P, Michaelis J. Survival of children with neuroblastoma: time trends and regional differences in Europe, 1978-1992. European Journal of Cancer 2001; 37:722-729.
6. Berthold F, Hero B, Breu H, Christiansen H, Erttmann R, Gnekow A, Herrmann F, Klingebiel T, Lampert F, Müller Weihrich S, Weinel P. The recurrence patterns of stages I, II and III neuroblastoma: experience with 77 relapsing patients. Annals of Oncoloyy 1996; 7:183-187.
7. Schilling FH, Spix C, Berthold F, Erttmann R, Hero B, Michaelis J, Sander J, Tafese T, Treuner J. German neuroblastoma mass screening study at 12 months of age: statistical aspects and preliminary results. Medical and Pediatric Oncology 1998; 31:435-441.
8. Schilling FH, Spix C, Berthold F, Erttmann R, Fehse N, Hero B, Klein G, Sander J, Schwarz K, Treuner J, Zorn U, Michaelis J. Neuroblastoma screening at one year of age. New England Journal of Medicine 2002; 346:1047-1053.
9. Day NE. The theoretical basis for cancer screening. In Advances in Cancer Screening, Miller AB (ed.). Kluwer Academic Publishers: Boston, 1996; 9-24.
10. Etzioni RD, Connor RJ, Prorok PC, Self SG. Design and analysis of cancer screening trials. Statistical Methods in Medical Research 1995; 4:3-17.
11. van Oortmarssen GJ. Screening, overview. In Encyclopedia of Biostatistics, Armitage P, Colton T (eds). Wiley: Chichester, 1998; 3985-3992.
12. Hakama M. Planning and designing of screening programmes. In Evaluation and Monitoring of Screening Programmes, Sankila R, Demaret E, Hakama M, Lynge E, Schouten LJ, Parkin DM (eds), for the European Network of Cancer Registries. European Commission, Europe Against Cancer Programme: Brussels-Luxembourg, 2000 (European Communities 2001; 13-28).
13. Ambros PF, Brodeur GM. Concept of tumorigenesis and regression. In Neuroblastoma, Brodeur GM, Sawada T, Tsuchida Y, Voute P (eds). Elsevier Science B.V.: Amsterdam, 2000; 21-32.
14. Berthold F, Hero B, Jobke A, Herz S, Boos J, Bretz R, Burdah S, Claviez A, Henze G, Jorch N, Klingebiel T, Kremens B, Kühl J, Schwabe D. Sind Spontanregressionen beim Neuroblastom verspätete embryofetale Involutionen? In Spontanremissionen in der Onkologie, Heim ME, Schwarz R (eds). Schattauer: Stuttgart, 1998; 84-94.
15. Black WC. Overdiagnosis: an underrecognized cause of confusion and harm in cancer screening (editorial). Journal of the National Cancer Institute 2000; 92:1280-1282.
16. Estève J , Parker L, Roy P, Herrmann F, Duffy S, Frappaz D, Lasset C, Hill C, Sancho-Garnier C, Michaelis J, Philip T. Is neuroblastoma screening evaluation needed and feasible? British Journal of Cancer 1995; 71: 1125-1131 (erratum, British Journal of Cancer 1995; 72:804).
17. Treuner J, Schilling FH. Neuroblastoma mass screening: the arguments for and against. European Journal of Cancer 1995; 31A:565-568.
18. Morrison AS. Screening in Chronic Disease. Oxford University Press: Oxford, 1992.
19. Duffy SW. Sojourn time in disease screening. In Encyclopedia of Biostatistics, Armitage P, Colton T (eds). Wiley: Chichester, 1998; 4187-4190.
20. Etzioni R, Self SG. On the catch-up time method for analyzing cancer screening trials. Biometrics 1995; 51: 31-43.
21. Estéve J, Roy P, Chauvin F, Philip T. Screening for neuroblastoma in children: Elements for a statistical evaluation. Medical and Pediatric Oncoloqy 1998; 31:401-407.
22. Bergeron C, Tafese T, Kerbl R, Craft A, Mann J, Frappaz D on behalf of the SENSE group. European Experience with screening for neuroblastoma before the age of 12 months. Medical and Pediatric Oncology 1998; 31: 442-449.
23. Woods WG, Tuchmann M, Robison LL, Bernstein M, Leclerc JM, Brisson LC, Brossard J, Hill G, Shister J, Luepker R, Byrne T, Weitzman S, Bunin G, Lemieux B, Brodeur GM. Screening for neuroblastoma is ineffective in reducing the incidence of unfavorable advanced stage disease in older children. European Journal of Cancer 1997; 33:2105-2112.
24. Woods WG, Gao RN, Shuster JJ, Robinson LL, Bernstein M, Weitzman S, Bunin G, Levy I, Brossard J, Dougherty G, Tuchman M, Lenieux B. Screening of infants and mortality due to neuroblastoma. New England Journal of Medicine 2002; 346:1041-1046.
25. Ajiki W, Tsukuma H, Oshima A, Kawa K. Effects of mass screening for neuroblastoma on incidence, mortality, and survival rates in Osaka, Japan. Cancer Causes and Control 1998; 9:631-636.
26. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year Survival rates Evidence of Success Against Cancer? Journal of the American Medical Association 2000; 283:2975-2978.
27. Powell JE, Esteve J, Mann JR, Parker L, Frappaz D, Michaelis J, Kerbl R, Mutz ID, Stiller CA, on behalf of SENSE. Neuroblastoma in Europe: differences in the pattern of disease in the UK. Lancet 1998; 352:682-687.